| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 31, 2025 9:00 A.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/7/2022 | $7.50 | Equal-Weight | Morgan Stanley |
EFFECT - Senti Biosciences, Inc. (0001854270) (Filer)
EFFECT - Senti Biosciences, Inc. (0001854270) (Filer)
424B5 - Senti Biosciences, Inc. (0001854270) (Filer)
– Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission – – Strengthened balance sheet with gross proceeds of approximately $47.6 million from private investment in public equity (PIPE) financing – SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter of 2024 and provided a summary of rece
SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio," or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Feng Hsiung, an executive with extensive business, finance and investment experience, to the Senti Bio Board of Directors (the "Board"). "We are pleased to welcome Feng to our Board—he brings deep expertise in investment strategy and capital markets across multiple industries," said Timothy Lu, M.D., Ph.D., CEO of Senti Bio. "We look forward to the unique business perspectives he'll pro
– Jay Cross, proven financial leader, appointed as CFO to drive strategic growth – – Faraz Siddiqui, expert in manufacturing operations, joins as SVP Technical Operations – SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced an expansion of its senior leadership team with the addition of Jay Cross as Chief Financial Officer and Faraz Siddiqui as Senior Vice President of Technical Operations. Mr. Cross will join the Company on March 3, 2025. Mr. Siddiqui joined
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
3 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
Morgan Stanley initiated coverage of Senti Bio with a rating of Equal-Weight and set a new price target of $7.50
SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio," or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Feng Hsiung, an executive with extensive business, finance and investment experience, to the Senti Bio Board of Directors (the "Board"). "We are pleased to welcome Feng to our Board—he brings deep expertise in investment strategy and capital markets across multiple industries," said Timothy Lu, M.D., Ph.D., CEO of Senti Bio. "We look forward to the unique business perspectives he'll pro
– Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in hepatocellular carcinoma ("HCC") – SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the first patient has been dosed in the pilot trial of SN301A in HCC in mainland China in collaboration with Celest Therapeutics (Shanghai) Co. Ltd ("Celest"). SN301A utilizes the anti-GPC3 + crIL-15 (each as defined below) SENTI-301A Gene
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that on November 26, 2024, the Compensation Committee of Senti Bio's Board of Directors granted to three new employees stock options to purchase an aggregate of 49,778 shares of the Company's common stock with a per share exercise price of $2.11. These awards were made under the Company's 2022 Inducement Equity Plan (the "Plan"). The above-described awards were each granted as an inducement material to the employees entering
SC 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)
SC 13G - Senti Biosciences, Inc. (0001854270) (Subject)
SC 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)